Reuters logo
BRIEF-Sangamo receives fast track status from the FDA for SB-318 and SB-913
2017年7月13日 / 晚上8点21分 / 4 个月前

BRIEF-Sangamo receives fast track status from the FDA for SB-318 and SB-913

July 13 (Reuters) - Sangamo Therapeutics Inc

* Sangamo receives fast track designation from the FDA for SB-318 and SB-913 in vivo genome editing product candidates for the treatment of MPS I and MPS II Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below